ClinicalTrials.gg
CompletedNCT00913627Updated Mar 22, 2018Results posted

Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain

A Phase 2 interventional study of ibuprofen and ibuprofen in Pain, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-03-22.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
16 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
26th of 86
196 · median 100
Started
2009
with 3 others
Phase 2
8 of 86
1 open now
Registered
12th of 86
by date
Lead sponsor
8 of 86
Pfizer

Among the 86 studies testing ibuprofen in Pain, this one is the 26th largest by enrollment, is one of 4 that started in 2009, is one of 8 in phase 2, and was the 12th registered.

Pain

10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 16 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of a single dose of an ibuprofen 600 mg extended release formulation in post-operative dental pain. There is concern that the manufacturing process may affect the performance characteristics of the selected prototype. Therefore, two formulations of this prototype manufactured by two different processes, [roller compaction] and [wet granulation] will be included in this study. The preferred prototype manufactured by two different methods will be compared to placebo and each other. This study will also characterize the pharmacokinetic/pharmacodynamic relationship with these formulations.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Extended-release
  • ibuprofen
04

Who can participate

Ages eligible
16 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

INCLUSION CRITERIA:

  • Males and females 16 to 40 years of age.
  • Outpatients who undergo surgical extraction of 1-2 third molars, one of which must be a partial or full bony mandibular impaction and have moderate to severe post-operative pain (confirmed by a VAS score of at least 50 mm on a 100 mm VAS) following surgical extraction;
  • Use of only the following preoperative medication(s)/anesthetic(s): short-acting local anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor, nitrous oxide, and/or midazolam;
  • Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form;
  • Examined by the attending dentist or physician and medically cleared to participate in the study;
  • In general good health and have no to the study medication.

Exclusion Criteria:

EXCLUSION CRITERIA:

  • Pregnancy, as verified by a urine-based pregnancy test, or breast feeding;
  • Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly controlled diabetes, significantly impaired cardiac, renal or hepatic function, poorly-controlled hyper- or hypothyroidism);
  • Use of a prescription or nonprescription drug with which the administration of ibuprofen or any other NSAID is contraindicated;
  • Use of a bisphosphonate (e.g., risedronate [Actonel], alendronate [Fosamax], or ibandronate [Boniva]) in the past 5-years;
  • Acute localized dentalveolar infection at the time of surgery that could confound the post-surgical evaluation;
  • Females who are of , or for less than 2 years and not using a medically approved method of (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test;
  • Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic ulcer disease;
  • History of alcoholism (i.e., on average, consumes 3 or more alcoholic drinks per day) or substance abuse within the last year, or is currently abusing alcohol or other mood-altering drugs (e.g., cannabis). Patients who are taking CNS or other psychotropic drugs (including St. John's Wort, or any other nutritional supplement known to have psychotropic effects) may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled;
  • Habituation to analgesic drugs (i.e., routine use of oral analgesics 5 or more times per week)
  • History of allergic reaction (e.g., asthma, rhinitis, swelling, shock, or hives) to ibuprofen, naproxen, aspirin, or to any other NSAID; or to codeine, hydrocodone, or acetaminophen, or to their combinations;
  • Prior use of any type of analgesic or NSAID five half-lives of that drug or less before taking the first dose of study medication, except for pre-anesthetic medication and anesthesia for the procedure;
  • Ingestion of any caffeine-containing beverages, chocolate, or alcohol 4 hours or less before taking the first dose of study medication;
  • The subject has taken an product or participated in an investigational trial within 30 days of study enrollment;
  • The subject has previously participated in this study;
  • The subject is a member of the study site staff directly involved with the study, an employee of the Sponsor, or a relative of study site personnel directly involved with the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
196 participants (actual)

Study arms

  • Experimental
    1

    1 x 600 mg ibuprofen IR/ER-roller compaction caplet

    Drug: ibuprofen

  • Experimental
    2

    1 x 600 mg ibuprofen IR/ER-Wet granulation caplet

    Drug: ibuprofen

  • Active comparator
    3

    1x 220 mg naproxen sodium (Aleve caplet)

    Drug: naproxen

  • Placebo comparator
    4

    1 x placebo caplet

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)

    Pain intensity difference (PID) score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -12 to 36 where higher positive values indicated improvement (decrease in pain intensity).

    Time frame: Baseline (0 hour) to 12 hours post dose

  2. Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)

    PID score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).

    Time frame: 8 to 12 hours post dose

Secondary outcomes

  1. Time to First Perceptible Pain Relief

    Time to first perceptible relief (confirmed by meaningful relief) was defined as the elapsed time from dosing until the participant depresses the first stopwatch labelled "first perceptible relief", if the participant also depressed the second stopwatch labelled as "meaningful relief" by 6 hours. If the confirmation was not achieved, the participant was censored at 6 hours. Perceptible relief defined as when participant first begins to feel any pain relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she has currently.

    Time frame: Baseline to 6 hours

  2. Time to Treatment Failure

    Time to first rescue medication or discontinuation due to lack of efficacy

    Time frame: Baseline to 24 hours

  3. Percentage of Participants With Treatment Failure

    Treatment failure defined as use of rescue medication or discontinuation due to lack of efficacy.

    Time frame: 8, 9, 10, 11, and 12 hours

  4. Time-weighted Sum of Pain Intensity Difference From 0 to 4 Hours (SPID 0-4) and 4 to 8 Hours (SPID 4-8)

    Time-weighted sum of PID score. PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).

    Time frame: 0 to 4 hours and 4 to 8 hours

  5. Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores (SPRID)

    Time-weighted sum of PRID score where PRID=PID+PR. PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline, ranged from -1 to 3. Baseline pain intensity score of at least 2 required for enrollment. Higher positive PID values = improvement. PR: 5-point categorical pain relief scale None (0), A Little (1), Some (2), A Lot (3) or Complete (4). SPRID 0-4, SPRID 4-8, and SRID 8-12 scores ranged from -4 to 28, SPRID 0-12 ranged from -12 to 84, higher scores = greater improvement.

    Time frame: 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours

  6. Time-weighted Sum of Pain Relief Scores (TOTPAR)

    TOTPAR based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief). For time-weighted sum of pain relief scores from 0 to 4 hours (TOTPAR 0-4), from 4 to 8 hours (TOTPAR 4-8), and from 8 to 12 hours (TOTPAR 8-12): range of scores 0 (worst) to 16 (best). TOTPAR 0-12 range of scores 0 (worst) to 48 (best).

    Time frame: 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours

  7. Percentage of Participants Achieving First Perceptible Relief Confirmed by Meaningful Relief

    The elapsed time from dosing until the participant indicated first perceptible relief, provided the participant also indicated achieving meaningful relief. Perceptible relief defined as when participant first begins to feel any pain-relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she currently has now.

    Time frame: 15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes

  8. Time to Meaningful Pain Relief

    Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that is considered meaningful to the participant.

    Time frame: Baseline to 6 hours

  9. Percentage of Participants Achieving Meaningful Pain Relief

    Participants evaluated the time to first perceptible pain relief by depressing a stopwatch at the moment they first began to experience perceptible relief and the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief defined as relief from the pain that is considered meaningful to the participant.

    Time frame: 15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes

  10. Participant Global Evaluation of Study Medication at 12 Hours

    Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).

    Time frame: 12 hours

  11. Participant Global Evaluation of Study Medication at 24 Hours

    Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).

    Time frame: 24 hours

  12. Pain Intensity Difference (PID) Score

    PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). PID score derived by subtracting postdose score from baseline score and could range from -1 to 3. A baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated greater improvement (decrease in pain intensity).

    Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours

  13. Pain Relief (PR) Score

    PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None \[0\], A Little \[1\], Some \[2\], A Lot \[3\] or Complete \[4\]. Higher scores indicated improvement (better pain relief).

    Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours

  14. Pain Relief Combined With Pain Intensity Difference (PRID) Score

    PRID=PID+PR, where PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline and could range from -1 to 3. Baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated improvement. PR: 5-point categorical pain relief scale (None \[0\], A Little \[1\], Some \[2\], A Lot \[3\], Complete \[4\]). PRID score could range from -1 to 7 where higher scores indicated better pain relief and decrease in pain intensity.

    Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours

  15. Peak Pain Relief Score

    Maximum PR score over the scheduled pain relief assessments. PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief).

    Time frame: Baseline to 12 hours

07

Results

Posted Mar 22, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Started29535658
Completed29535658
Not completed0000

Outcome measures

PrimaryTime-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)

Pain intensity difference (PID) score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -12 to 36 where higher positive values indicated improvement (decrease in pain intensity).

Time frame:
Baseline (0 hour) to 12 hours post dose
Reported as:
Mean · units on a scale
Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)0.05 ± 9.2216.87 ± 9.3517.34 ± 10.5412.66 ± 10.02
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline pain severity rating (PSR) and gender) · Mean difference (final values): 16.16 · 95% CI 12.13 to 20.19
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline pain severity rating (PSR) and gender) · Mean difference (final values): 17.00 · 95% CI 13.02 to 20.99
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline pain severity rating (PSR) and gender) · Mean difference (final values): 12.30 · 95% CI 8.33 to 16.26
PrimaryTime-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)

PID score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).

Time frame:
8 to 12 hours post dose
Reported as:
Mean · units on a scale
Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)-0.03 ± 4.056.57 ± 4.447.14 ± 5.245.14 ± 5.02
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 6.34 · 95% CI 4.30 to 8.38
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 7.06 · 95% CI 5.05 to 9.08
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 5.05 · 95% CI 3.04 to 7.06
SecondaryTime to First Perceptible Pain Relief

Time to first perceptible relief (confirmed by meaningful relief) was defined as the elapsed time from dosing until the participant depresses the first stopwatch labelled "first perceptible relief", if the participant also depressed the second stopwatch labelled as "meaningful relief" by 6 hours. If the confirmation was not achieved, the participant was censored at 6 hours. Perceptible relief defined as when participant first begins to feel any pain relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she has currently.

Time frame:
Baseline to 6 hours
Reported as:
Median · minutes
Time to First Perceptible Pain Relief
minutesPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Time to First Perceptible Pain ReliefNA (NA to NA)29.4 (23.3 to 35.3)29.4 (26.1 to 36.2)32.1 (29.5 to 58.0)
SecondaryTime to Treatment Failure

Time to first rescue medication or discontinuation due to lack of efficacy

Time frame:
Baseline to 24 hours
Reported as:
Median · hours
Time to Treatment Failure
hoursPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Time to Treatment Failure1.7 (1.7 to 2.2)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Treatment Failure

Treatment failure defined as use of rescue medication or discontinuation due to lack of efficacy.

Time frame:
8, 9, 10, 11, and 12 hours
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Failure
percentage of participantsPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
8 hours82.811.312.524.1
9 hours82.811.312.525.9
10 hours82.817.012.527.6
11 hours82.820.814.327.6
12 hours82.820.817.932.8
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -72.19 · 95% CI -88.56 to -55.83CMH adjusted proportions
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -70.72 · 95% CI -87.14 to -54.30CMH adjusted proportions
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -59.60 · 95% CI -76.94 to -42.27CMH adjusted proportions
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -72.19 · 95% CI -88.56 to -55.83CMH adjusted proportions
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -70.72 · 95% CI -87.14 to -54.30CMH adjusted proportions
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -57.79 · 95% CI -75.43 to -40.16CMH adjusted proportions
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -66.79 · 95% CI -83.98 to -49.60CMH adjusted proportions
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -70.72 · 95% CI -87.14 to -54.30CMH adjusted proportions
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cochran-mantel-haenszel (cmh): -55.98 · 95% CI -73.85 to -38.11CMH adjusted proportions
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: -63.44 · 95% CI -80.82 to -46.06
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: -68.88 · 95% CI -85.63 to -54.14
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: -55.98 · 95% CI -73.85 to -38.11
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: -63.44 · 95% CI -80.82 to -46.06
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: -65.28 · 95% CI -82.49 to -48.07
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: -50.77 · 95% CI -69.09 to -32.45
SecondaryTime-weighted Sum of Pain Intensity Difference From 0 to 4 Hours (SPID 0-4) and 4 to 8 Hours (SPID 4-8)

Time-weighted sum of PID score. PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).

Time frame:
0 to 4 hours and 4 to 8 hours
Reported as:
Mean · units on a scale
Time-weighted Sum of Pain Intensity Difference From 0 to 4 Hours (SPID 0-4) and 4 to 8 Hours (SPID 4-8)
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
SPID 0-4-0.12 ± 2.575.44 ± 3.215.22 ± 2.903.96 ± 2.87
SPID 4-80.31 ± 4.578.15 ± 4.488.13 ± 4.765.95 ± 4.74
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR, and gender) · Mean difference (final values): 5.34 · 95% CI 4.18 to 6.51
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 5.25 · 95% CI 4.09 to 6.40
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.98 · 95% CI 2.83 to 5.12
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 7.53 · 95% CI 5.63 to 9.43
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 7.68 · 95% CI 5.80 to 9.56
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 5.49 · 95% CI 3.62 to 7.36
SecondaryTime-weighted Sum of Pain Relief and Pain Intensity Difference Scores (SPRID)

Time-weighted sum of PRID score where PRID=PID+PR. PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline, ranged from -1 to 3. Baseline pain intensity score of at least 2 required for enrollment. Higher positive PID values = improvement. PR: 5-point categorical pain relief scale None (0), A Little (1), Some (2), A Lot (3) or Complete (4). SPRID 0-4, SPRID 4-8, and SRID 8-12 scores ranged from -4 to 28, SPRID 0-12 ranged from -12 to 84, higher scores = greater improvement.

Time frame:
0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours
Reported as:
Mean · units on a scale
Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores (SPRID)
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
SPRID 0-41.78 ± 5.4515.48 ± 6.6015.12 ± 6.1011.97 ± 6.51
SPRID 4-83.69 ± 10.6323.21 ± 8.8523.14 ± 10.1217.71 ± 10.69
SPRID 8-123.00 ± 9.3819.36 ± 9.9420.73 ± 11.4315.86 ± 11.56
SPRID 0-127.09 ± 21.0048.76 ± 18.9950.01 ± 22.3238.45 ± 22.61
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 13.47 · 95% CI 10.68 to 16.27
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 13.24 · 95% CI 10.48 to 16.01
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 10.08 · 95% CI 7.33 to 12.83
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 19.21 · 95% CI 14.71 to 23.71
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 19.32 · 95% CI 14.86 to 23.78
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 13.87 · 95% CI 9.44 to 18.30
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 16.18 · 95% CI 11.29 to 21.07
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 17.65 · 95% CI 12.81 to 22.49
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 12.78 · 95% CI 7.97 to 17.59
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 41.08 · 95% CI 31.48 to 50.69
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 42.66 · 95% CI 33.15 to 52.17
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 31.08 · 95% CI 21.63 to 40.53
SecondaryTime-weighted Sum of Pain Relief Scores (TOTPAR)

TOTPAR based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief). For time-weighted sum of pain relief scores from 0 to 4 hours (TOTPAR 0-4), from 4 to 8 hours (TOTPAR 4-8), and from 8 to 12 hours (TOTPAR 8-12): range of scores 0 (worst) to 16 (best). TOTPAR 0-12 range of scores 0 (worst) to 48 (best).

Time frame:
0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours
Reported as:
Mean · units on a scale
Time-weighted Sum of Pain Relief Scores (TOTPAR)
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
TOTPAR 0-41.91 ± 3.2510.04 ± 3.669.90 ± 3.518.01 ± 3.96
TOTPAR 4-83.38 ± 6.4315.06 ± 4.7615.02 ± 5.7911.76 ± 6.35
TOTPAR 8-123.03 ± 5.7512.79 ± 5.9713.59 ± 6.6110.72 ± 6.89
TOTPAR 0-127.04 ± 12.7431.89 ± 10.6732.67 ± 12.7425.79 ± 13.48
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 8.13 · 95% CI 6.45 to 9.80
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 7.99 · 95% CI 6.34 to 9.65
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 6.11 · 95% CI 4.46 to 7.75
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 11.68 · 95% CI 9.02 to 14.34
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 11.64 · 95% CI 9.01 to 14.27
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 8.38 · 95% CI 5.76 to 11.00
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 9.84 · 95% CI 6.93 to 12.75
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 10.59 · 95% CI 7.71 to 13.46
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 7.73 · 95% CI 4.87 to 10.59
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 24.93 · 95% CI 19.24 to 30.61
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 25.66 · 95% CI 20.03 to 31.28
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 18.78 · 95% CI 13.19 to 24.38
SecondaryPercentage of Participants Achieving First Perceptible Relief Confirmed by Meaningful Relief

The elapsed time from dosing until the participant indicated first perceptible relief, provided the participant also indicated achieving meaningful relief. Perceptible relief defined as when participant first begins to feel any pain-relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she currently has now.

Time frame:
15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes
Reported as:
Number · percentage of participants
Percentage of Participants Achieving First Perceptible Relief Confirmed by Meaningful Relief
percentage of participantsPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
15 minutes3.417.019.68.6
30 minutes3.452.855.439.7
45 minutes6.964.273.256.9
60 minutes13.881.183.965.5
90 minutes13.883.087.572.4
120 minutes13.883.091.172.4
180 minutes13.883.091.172.4
240 minutes13.883.091.172.4
300 minutes13.883.091.172.4
360 minutes13.883.091.172.4
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = 0.080 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 13.31 · 95% CI 1.26 to 25.36
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = 0.043 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 16.39 · 95% CI 3.73 to 29.04
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = 0.354 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 5.39 · 95% CI -4.62 to 15.40
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 48.65 · 95% CI 33.34 to 63.96
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 51.94 · 95% CI 37.15 to 66.73
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 36.80 · 95% CI 22.62 to 50.98
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 57.39 · 95% CI 41.20 to 73.57
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 66.67 · 95% CI 51.56 to 81.78
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 50.20 · 95% CI 34.20 to 66.21
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 67.64 · 95% CI 51.36 to 83.93
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 70.61 · 95% CI 55.16 to 86.05
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 51.85 · 95% CI 34.32 to 69.38
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 69.33 · 95% CI 53.33 to 85.33
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 74.21 · 95% CI 59.29 to 89.14
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 58.86 · 95% CI 41.88 to 75.84
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 69.33 · 95% CI 53.33 to 85.33
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 77.82 · 95% CI 63.57 to 92.06
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 58.86 · 95% CI 41.88 to 75.84
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 69.33 · 95% CI 53.33 to 85.33
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 77.82 · 95% CI 63.57 to 92.06
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 58.86 · 95% CI 41.88 to 75.84
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 69.33 · 95% CI 53.33 to 85.33
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 77.82 · 95% CI 63.57 to 92.06
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 58.86 · 95% CI 41.88 to 75.84
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 69.33 · 95% CI 53.33 to 85.33
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 77.82 · 95% CI 63.57 to 92.06
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 58.86 · 95% CI 41.88 to 75.84
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 69.33 · 95% CI 53.33 to 85.33
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 77.82 · 95% CI 63.57 to 92.06
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 58.86 · 95% CI 41.88 to 75.84
SecondaryTime to Meaningful Pain Relief

Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that is considered meaningful to the participant.

Time frame:
Baseline to 6 hours
Reported as:
Median · minutes
Time to Meaningful Pain Relief
minutesPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Time to Meaningful Pain ReliefNA (NA to NA)59.7 (52.3 to 88.3)76.7 (56.5 to 99.3)84.1 (63.8 to 174.2)
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Proportional hazards regression · p = <0.001 (p-value adjusted for gender and categorical baseline pain severity) · Hazard ratio, log: 13.56 · 95% CI 4.85 to 37.89
SecondaryPercentage of Participants Achieving Meaningful Pain Relief

Participants evaluated the time to first perceptible pain relief by depressing a stopwatch at the moment they first began to experience perceptible relief and the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief defined as relief from the pain that is considered meaningful to the participant.

Time frame:
15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Meaningful Pain Relief
percentage of participantsPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
15 minutes0.01.90.01.7
30 minutes0.09.410.73.4
45 minutes3.428.328.613.8
60 minutes3.450.939.331.0
90 minutes3.464.257.150.0
120 minutes6.971.771.456.9
180 minutes10.379.282.163.8
240 minutes10.383.089.367.2
300 minutes10.383.091.169.0
360 minutes13.883.091.172.4
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = 0.434 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 2.03 · 95% CI -1.95 to 6.02
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · Cmh adjusted proportions: 0.00 · 95% CI 0.00 to 0.00
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = 0.469 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 1.78 · 95% CI -1.71 to 5.27
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = 0.101 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 9.13 · 95% CI 1.33 to 16.93
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = 0.069 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 10.73 · 95% CI 2.54 to 18.91
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = 0.303 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 3.59 · 95% CI -1.39 to 8.57
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = 0.008 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 24.58 · 95% CI 10.68 to 38.47
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = 0.007 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 25.31 · 95% CI 11.35 to 39.28
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = 0.129 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 10.62 · 95% CI -0.68 to 21.92
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 47.72 · 95% CI 32.25 to 63.19
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 36.01 · 95% CI 21.24 to 50.78
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = 0.003 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 27.87 · 95% CI 13.93 to 41.81
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 61.01 · 95% CI 46.12 to 75.89
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 53.83 · 95% CI 38.85 to 68.80
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 46.74 · 95% CI 31.89 to 61.58
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 64.78 · 95% CI 49.37 to 80.18
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 64.80 · 95% CI 50.01 to 79.59
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 50.19 · 95% CI 34.27 to 66.11
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 68.59 · 95% CI 52.81 to 84.38
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 72.16 · 95% CI 57.05 to 87.26
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 53.47 · 95% CI 36.57 to 70.37
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 72.66 · 95% CI 57.48 to 87.84
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 79.36 · 95% CI 65.68 to 93.05
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 57.03 · 95% CI 40.46 to 73.60
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 72.66 · 95% CI 57.48 to 87.84
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 81.20 · 95% CI 67.91 to 94.49
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 58.84 · 95% CI 42.34 to 75.35
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 69.33 · 95% CI 53.33 to 85.33
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 77.82 · 95% CI 63.57 to 92.06
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value adjusted for baseline PSR and gender) · Cmh adjusted proportions: 58.86 · 95% CI 41.88 to 75.84
SecondaryParticipant Global Evaluation of Study Medication at 12 Hours

Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).

Time frame:
12 hours
Reported as:
Number · participants
Participant Global Evaluation of Study Medication at 12 Hours
participantsPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Very poor20227
Poor4101
Fair1348
Good211918
Very good2202815
Excellent016139
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value from CMH test with modified ridit scores, adjusted for baseline PSR and gender) · Goodman-kruskal gamma statistic: 0.93 · 95% CI 0.85 to 1.01
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value from CMH test with modified ridit scores, adjusted for baseline PSR and gender) · Goodman-kruskal gamma statistic: 0.95 · 95% CI 0.88 to 1.02
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value from CMH test with modified ridit scores, adjusted for baseline PSR and gender) · Goodman-kruskal gamma statistic: 0.84 · 95% CI 0.70 to 0.98
SecondaryParticipant Global Evaluation of Study Medication at 24 Hours

Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).

Time frame:
24 hours
Reported as:
Number · participants
Participant Global Evaluation of Study Medication at 24 Hours
participantsPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Very poor20227
Poor4101
Fair1234
Good3141017
Very good1172319
Excellent0161810
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · Cochran-Mantel-Haenszel · p = <0.001 (p-value from CMH test with modified ridit scores, adjusted for baseline PSR and gender) · Goodman-kruskal gamma statistic: 0.93 · 95% CI 0.85 to 1.01
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · Cochran-Mantel-Haenszel · p = <0.001 (p-value from CMH test with modified ridit scores, adjusted for baseline PSR and gender) · Goodman-kruskal gamma statistic: 0.96 · 95% CI 0.91 to 1.01
  • Placebo vs Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (p-value from CMH test with modified ridit scores, adjusted for baseline PSR and gender) · Goodman-kruskal gamma statistic: 0.89 · 95% CI 0.79 to 0.99
SecondaryPain Intensity Difference (PID) Score

PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). PID score derived by subtracting postdose score from baseline score and could range from -1 to 3. A baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated greater improvement (decrease in pain intensity).

Time frame:
15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
Reported as:
Mean · units on a scale
Pain Intensity Difference (PID) Score
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
15 minutes-0.14 ± 0.440.09 ± 0.450.09 ± 0.350.05 ± 0.22
30 minutes-0.14 ± 0.520.40 ± 0.690.34 ± 0.640.29 ± 0.53
45 minutes-0.10 ± 0.560.77 ± 0.890.70 ± 0.780.53 ± 0.60
60 minutes-0.10 ± 0.620.94 ± 0.991.00 ± 0.810.81 ± 0.76
90 minutes-0.07 ± 0.591.25 ± 1.021.29 ± 0.871.05 ± 0.80
2 hours0.00 ± 0.651.51 ± 0.971.48 ± 0.911.05 ± 0.83
3 hours0.00 ± 0.851.70 ± 0.971.64 ± 0.881.24 ± 0.94
4 hours0.03 ± 0.941.81 ± 0.921.66 ± 0.941.24 ± 0.98
5 hours0.07 ± 0.921.74 ± 0.941.68 ± 0.971.22 ± 1.04
6 hours0.07 ± 0.921.62 ± 0.991.66 ± 0.981.22 ± 1.04
7 hours0.07 ± 0.921.51 ± 0.971.64 ± 0.981.12 ± 1.01
8 hours0.07 ± 0.921.47 ± 0.911.48 ± 1.061.14 ± 1.00
9 hours0.00 ± 0.801.34 ± 0.941.41 ± 1.061.00 ± 1.03
10 hours-0.03 ± 0.781.26 ± 0.961.45 ± 1.111.02 ± 1.05
11 hours-0.03 ± 0.821.23 ± 0.971.43 ± 1.111.03 ± 1.11
12 hours-0.03 ± 0.821.26 ± 0.961.38 ± 1.090.95 ± 1.08
13 hours0.00 ± 0.851.25 ± 1.021.23 ± 1.140.95 ± 1.03
14 hours0.03 ± 0.911.15 ± 1.101.18 ± 1.150.93 ± 1.06
16 hours-0.03 ± 0.821.08 ± 1.051.02 ± 1.100.95 ± 1.07
24 hours0.07 ± 1.000.89 ± 1.010.91 ± 1.130.97 ± 1.08
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = 0.008 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.22 · 95% CI 0.06 to 0.38
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = 0.007 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.22 · 95% CI 0.06 to 0.38
  • Placebo vs Naproxen · ANOVA · p = 0.024 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.18 · 95% CI 0.02 to 0.34
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.51 · 95% CI 0.24 to 0.78
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.47 · 95% CI 0.20 to 0.73
  • Placebo vs Naproxen · ANOVA · p = 0.002 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.42 · 95% CI 0.16 to 0.68
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.85 · 95% CI 0.52 to 1.17
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.79 · 95% CI 0.47 to 1.11
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.62 · 95% CI 0.30 to 0.94
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.01 · 95% CI 0.65 to 1.37
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.09 · 95% CI 0.73 to 1.44
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.90 · 95% CI 0.54 to 1.25
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.26 · 95% CI 0.90 to 1.63
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.33 · 95% CI 0.97 to 1.69
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.10 · 95% CI 0.74 to 1.45
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.45 · 95% CI 1.09 to 1.82
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.46 · 95% CI 1.10 to 1.82
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.03 · 95% CI 0.67 to 1.38
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.63 · 95% CI 1.26 to 2.00
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.61 · 95% CI 1.25 to 1.98
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.21 · 95% CI 0.85 to 1.57
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.71 · 95% CI 1.33 to 2.08
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.60 · 95% CI 1.23 to 1.97
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.17 · 95% CI 0.81 to 1.54
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.60 · 95% CI 1.20 to 2.00
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.58 · 95% CI 1.19 to 1.98
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.12 · 95% CI 0.73 to 1.52
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.49 · 95% CI 1.08 to 1.90
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.56 · 95% CI 1.16 to 1.97
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.13 · 95% CI 0.72 to 1.53
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.38 · 95% CI 0.97 to 1.79
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.55 · 95% CI 1.14 to 1.95
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.02 · 95% CI 0.62 to 1.43
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.35 · 95% CI 0.93 to 1.77
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.39 · 95% CI 0.97 to 1.81
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.04 · 95% CI 0.63 to 1.46
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.29 · 95% CI 0.87 to 1.71
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.39 · 95% CI 0.97 to 1.81
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.98 · 95% CI 0.56 to 1.39
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.25 · 95% CI 0.82 to 1.68
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.46 · 95% CI 1.03 to 1.89
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.03 · 95% CI 0.60 to 1.45
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.21 · 95% CI 0.77 to 1.64
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.44 · 95% CI 1.00 to 1.87
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.04 · 95% CI 0.61 to 1.48
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.25 · 95% CI 0.81 to 1.68
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.39 · 95% CI 0.96 to 1.82
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.96 · 95% CI 0.53 to 1.39
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.20 · 95% CI 0.75 to 1.64
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.21 · 95% CI 0.77 to 1.65
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.93 · 95% CI 0.49 to 1.36
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.07 · 95% CI 0.60 to 1.53
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.12 · 95% CI 0.66 to 1.58
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.87 · 95% CI 0.42 to 1.33
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.06 · 95% CI 0.61 to 1.51
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.03 · 95% CI 0.58 to 1.48
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.96 · 95% CI 0.52 to 1.40
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = 0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.77 · 95% CI 0.31 to 1.24
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.82 · 95% CI 0.36 to 1.28
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.88 · 95% CI 0.42 to 1.33
SecondaryPain Relief (PR) Score

PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None \[0\], A Little \[1\], Some \[2\], A Lot \[3\] or Complete \[4\]. Higher scores indicated improvement (better pain relief).

Time frame:
15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
Reported as:
Mean · units on a scale
Pain Relief (PR) Score
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
15 minutes0.07 ± 0.260.36 ± 0.710.29 ± 0.560.28 ± 0.64
30 minutes0.21 ± 0.621.02 ± 0.990.82 ± 0.860.79 ± 0.91
45 minutes0.31 ± 0.661.72 ± 1.211.55 ± 1.171.21 ± 1.07
60 minutes0.41 ± 0.682.04 ± 1.271.98 ± 1.171.67 ± 1.19
90 minutes0.41 ± 0.732.40 ± 1.292.50 ± 1.162.09 ± 1.19
2 hours0.55 ± 0.912.66 ± 1.212.77 ± 1.142.24 ± 1.19
3 hours0.55 ± 1.153.06 ± 1.053.04 ± 1.092.43 ± 1.20
4 hours0.62 ± 1.273.17 ± 0.983.07 ± 1.132.43 ± 1.27
5 hours0.66 ± 1.293.13 ± 0.983.07 ± 1.192.36 ± 1.37
6 hours0.72 ± 1.362.98 ± 1.073.09 ± 1.162.40 ± 1.40
7 hours0.72 ± 1.362.94 ± 1.013.02 ± 1.202.29 ± 1.39
8 hours0.66 ± 1.262.83 ± 1.122.77 ± 1.332.28 ± 1.42
9 hours0.66 ± 1.232.55 ± 1.312.77 ± 1.322.16 ± 1.41
10 hours0.59 ± 1.152.51 ± 1.322.77 ± 1.362.14 ± 1.41
11 hours0.59 ± 1.212.47 ± 1.322.71 ± 1.372.17 ± 1.46
12 hours0.55 ± 1.182.43 ± 1.382.57 ± 1.451.98 ± 1.52
13 hours0.62 ± 1.272.43 ± 1.462.39 ± 1.532.03 ± 1.50
14 hours0.66 ± 1.342.28 ± 1.492.27 ± 1.602.03 ± 1.57
16 hours0.59 ± 1.272.15 ± 1.472.00 ± 1.641.98 ± 1.57
24 hours0.69 ± 1.421.92 ± 1.531.77 ± 1.712.00 ± 1.58
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = 0.034 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.29 · 95% CI 0.02 to 0.57
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = 0.111 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.22 · 95% CI -0.05 to 0.49
  • Placebo vs Naproxen · ANOVA · p = 0.125 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.21 · 95% CI -0.06 to 0.48
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.81 · 95% CI 0.41 to 1.22
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = 0.003 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.61 · 95% CI 0.22 to 1.01
  • Placebo vs Naproxen · ANOVA · p = 0.004 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.59 · 95% CI 0.19 to 0.98
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.41 · 95% CI 0.91 to 1.91
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.24 · 95% CI 0.75 to 1.74
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.90 · 95% CI 0.41 to 1.39
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.63 · 95% CI 1.11 to 2.16
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.57 · 95% CI 1.05 to 2.09
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.26 · 95% CI 0.75 to 1.78
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.99 · 95% CI 1.46 to 2.52
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.09 · 95% CI 1.57 to 2.61
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.68 · 95% CI 1.16 to 2.20
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.12 · 95% CI 1.59 to 2.64
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.22 · 95% CI 1.70 to 2.74
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.69 · 95% CI 1.18 to 2.21
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.50 · 95% CI 1.98 to 3.01
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.48 · 95% CI 1.97 to 2.99
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.88 · 95% CI 1.37 to 2.38
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.54 · 95% CI 2.01 to 3.07
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.45 · 95% CI 1.92 to 2.97
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.81 · 95% CI 1.29 to 2.33
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.47 · 95% CI 1.92 to 3.03
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.41 · 95% CI 1.87 to 2.96
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.71 · 95% CI 1.16 to 2.25
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.26 · 95% CI 1.69 to 2.83
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.37 · 95% CI 1.80 to 2.93
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.67 · 95% CI 1.11 to 2.23
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.22 · 95% CI 1.66 to 2.79
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.30 · 95% CI 1.74 to 2.85
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.57 · 95% CI 1.02 to 2.13
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.19 · 95% CI 1.59 to 2.78
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.12 · 95% CI 1.53 to 2.70
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.63 · 95% CI 1.04 to 2.21
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.91 · 95% CI 1.30 to 2.52
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.12 · 95% CI 1.52 to 2.72
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.51 · 95% CI 0.91 to 2.11
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.94 · 95% CI 1.34 to 2.55
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.19 · 95% CI 1.59 to 2.79
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.56 · 95% CI 0.97 to 2.16
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.90 · 95% CI 1.28 to 2.52
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.13 · 95% CI 1.52 to 2.75
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.59 · 95% CI 0.98 to 2.20
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.90 · 95% CI 1.26 to 2.54
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.03 · 95% CI 1.39 to 2.66
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.44 · 95% CI 0.81 to 2.07
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.83 · 95% CI 1.17 to 2.49
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.78 · 95% CI 1.13 to 2.43
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.42 · 95% CI 0.78 to 2.07
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.64 · 95% CI 0.95 to 2.32
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.61 · 95% CI 0.94 to 2.29
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.38 · 95% CI 0.71 to 2.06
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.58 · 95% CI 0.88 to 2.27
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.42 · 95% CI 0.73 to 2.10
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.40 · 95% CI 0.72 to 2.08
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.25 · 95% CI 0.53 to 1.96
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = 0.003 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.08 · 95% CI 0.38 to 1.79
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.32 · 95% CI 0.61 to 2.02
SecondaryPain Relief Combined With Pain Intensity Difference (PRID) Score

PRID=PID+PR, where PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline and could range from -1 to 3. Baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated improvement. PR: 5-point categorical pain relief scale (None \[0\], A Little \[1\], Some \[2\], A Lot \[3\], Complete \[4\]). PRID score could range from -1 to 7 where higher scores indicated better pain relief and decrease in pain intensity.

Time frame:
15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
Reported as:
Mean · units on a scale
Pain Relief Combined With Pain Intensity Difference (PRID) Score
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
15 minutes-0.07 ± 0.590.45 ± 1.080.38 ± 0.840.33 ± 0.80
30 minutes0.07 ± 1.001.42 ± 1.601.16 ± 1.401.09 ± 1.37
45 minutes0.21 ± 1.082.49 ± 2.042.25 ± 1.901.74 ± 1.58
60 minutes0.31 ± 1.142.98 ± 2.182.98 ± 1.902.48 ± 1.86
90 minutes0.34 ± 1.203.64 ± 2.223.79 ± 1.923.14 ± 1.88
2 hours0.55 ± 1.454.17 ± 2.084.25 ± 1.973.29 ± 1.91
3 hours0.55 ± 1.924.75 ± 1.944.68 ± 1.873.67 ± 2.03
4 hours0.66 ± 2.134.98 ± 1.804.73 ± 1.973.67 ± 2.15
5 hours0.72 ± 2.144.87 ± 1.834.75 ± 2.083.59 ± 2.32
6 hours0.79 ± 2.214.60 ± 1.964.75 ± 2.063.62 ± 2.35
7 hours0.79 ± 2.214.45 ± 1.904.66 ± 2.083.41 ± 2.32
8 hours0.72 ± 2.104.30 ± 1.954.25 ± 2.303.41 ± 2.35
9 hours0.66 ± 1.953.89 ± 2.144.18 ± 2.293.16 ± 2.36
10 hours0.55 ± 1.823.77 ± 2.194.21 ± 2.383.16 ± 2.38
11 hours0.55 ± 1.943.70 ± 2.224.14 ± 2.393.21 ± 2.50
12 hours0.52 ± 1.923.70 ± 2.243.95 ± 2.452.93 ± 2.53
13 hours0.62 ± 2.033.68 ± 2.393.63 ± 2.592.98 ± 2.46
14 hours0.69 ± 2.173.43 ± 2.513.45 ± 2.682.97 ± 2.54
16 hours0.55 ± 2.013.23 ± 2.433.02 ± 2.672.93 ± 2.57
24 hours0.76 ± 2.342.81 ± 2.452.68 ± 2.782.97 ± 2.58
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = 0.011 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.52 · 95% CI 0.12 to 0.91
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = 0.028 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.44 · 95% CI 0.05 to 0.83
  • Placebo vs Naproxen · ANOVA · p = 0.048 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 0.39 · 95% CI 0.00 to 0.78
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.32 · 95% CI 0.69 to 1.96
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.08 · 95% CI 0.45 to 1.71
  • Placebo vs Naproxen · ANOVA · p = 0.002 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.01 · 95% CI 0.38 to 1.63
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.26 · 95% CI 1.46 to 3.06
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.03 · 95% CI 1.24 to 2.82
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.52 · 95% CI 0.74 to 2.31
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.64 · 95% CI 1.78 to 3.50
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.66 · 95% CI 1.81 to 3.51
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.16 · 95% CI 1.32 to 3.00
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.26 · 95% CI 2.39 to 4.12
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.42 · 95% CI 2.57 to 4.28
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.77 · 95% CI 1.92 to 3.63
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.57 · 95% CI 2.70 to 4.44
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.68 · 95% CI 2.82 to 4.53
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.72 · 95% CI 1.87 to 3.57
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 4.13 · 95% CI 3.27 to 4.99
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 4.09 · 95% CI 3.24 to 4.95
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.09 · 95% CI 2.24 to 3.93
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 4.25 · 95% CI 3.36 to 5.13
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 4.04 · 95% CI 3.17 to 4.92
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.98 · 95% CI 2.11 to 3.85
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 4.07 · 95% CI 3.14 to 5.01
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 4.00 · 95% CI 3.07 to 4.92
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.83 · 95% CI 1.91 to 3.75
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.75 · 95% CI 2.78 to 4.71
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.93 · 95% CI 2.98 to 4.89
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.80 · 95% CI 1.85 to 3.75
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.61 · 95% CI 2.65 to 4.56
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.84 · 95% CI 2.89 to 4.79
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.60 · 95% CI 1.65 to 3.54
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.54 · 95% CI 2.54 to 4.53
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.51 · 95% CI 2.52 to 4.49
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.67 · 95% CI 1.69 to 3.65
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.20 · 95% CI 2.19 to 4.21
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.51 · 95% CI 2.51 to 4.51
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.49 · 95% CI 1.49 to 3.48
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.19 · 95% CI 2.17 to 4.21
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.65 · 95% CI 2.64 to 4.66
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.59 · 95% CI 1.58 to 3.60
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.10 · 95% CI 2.06 to 4.15
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.57 · 95% CI 2.53 to 4.61
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.64 · 95% CI 1.61 to 3.67
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.15 · 95% CI 2.09 to 4.21
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.41 · 95% CI 2.36 to 4.46
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.40 · 95% CI 1.36 to 3.44
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 3.03 · 95% CI 1.94 to 4.12
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.99 · 95% CI 1.91 to 4.07
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.35 · 95% CI 1.28 to 3.42
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.70 · 95% CI 1.57 to 3.83
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.74 · 95% CI 1.62 to 3.85
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.26 · 95% CI 1.14 to 3.37
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.64 · 95% CI 1.51 to 3.76
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.45 · 95% CI 1.33 to 3.56
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.36 · 95% CI 1.25 to 3.47
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.02 · 95% CI 0.86 to 3.19
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = 0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 1.90 · 95% CI 0.75 to 3.05
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.19 · 95% CI 1.05 to 3.34
SecondaryPeak Pain Relief Score

Maximum PR score over the scheduled pain relief assessments. PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief).

Time frame:
Baseline to 12 hours
Reported as:
Mean · units on a scale
Peak Pain Relief Score
units on a scalePlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
Peak Pain Relief Score1.00 ± 1.413.42 ± 0.823.39 ± 0.853.05 ± 1.16
Statistical analysis
  • Placebo vs Ibuprofen IR/ER (Roller Compaction) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.42 · 95% CI 1.94 to 2.89
  • Placebo vs Ibuprofen IR/ER (Wet Granulation) · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.39 · 95% CI 1.92 to 2.86
  • Placebo vs Naproxen · ANOVA · p = <0.001 (p-value adjusted for baseline PSR and gender) · Mean difference (final values): 2.05 · 95% CI 1.58 to 2.52

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/29 (0%)8/29 (27.6%)
Ibuprofen IR/ER (Roller Compaction)—0/53 (0%)3/53 (5.7%)
Ibuprofen IR/ER (Wet Granulation)—0/56 (0%)8/56 (14.3%)
Naproxen—0/58 (0%)6/58 (10.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)Naproxen
NauseaGastrointestinal disorders6/291/535/562/58
VomitingGastrointestinal disorders5/290/533/561/58
HeadacheNervous system disorders1/292/531/561/58
DizzinessNervous system disorders1/290/532/562/58
MalaiseGeneral disorders0/291/530/560/58
EpistaxiaRespiratory, thoracic and mediastinal disorders0/291/530/560/58
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders0/291/530/560/58
PyrexiaGeneral disorders0/290/531/560/58
ParaesthesiaNervous system disorders0/290/531/560/58
PruritusSkin and subcutaneous tissue disorders0/290/531/560/58

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)NaproxenTotal
Mean18.1 ± 2.118.6 ± 2.418.7 ± 2.718.3 ± 2.618.5 ± 2.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)NaproxenTotal
Female1222232481
Male17313334115
Pain severity
Pain severity(participants)PlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)NaproxenTotal
Moderate18293334114
Severe1124232482
Pain intensity
Pain intensity(mm)PlaceboIbuprofen IR/ER (Roller Compaction)Ibuprofen IR/ER (Wet Granulation)NaproxenTotal
Mean73.90 ± 11.6077.06 ± 13.2374.80 ± 12.4075.12 ± 12.3075.37 ± 12.44
08

Study locations

1 site
  • Jean Brown Research Center
    Salt Lake City, Utah 84124, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2009 to primary completion in Aug 2009, 2 months.

Results were first posted in Mar 2018, 8 years 7 months after primary completion. A results delay was requested in Nov 2012.

Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 2 months is below that.

Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2009
First posted
Jun 4, 2009
StartActual
May 7, 2009
Primary completionActual
Aug 1, 2009
CompletionActual
Aug 5, 2009
Results delay requested
Nov 9, 2012
Results first posted
Mar 22, 2018
Last update
Mar 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00913627
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 4, 2009
Start date
May 7, 2009
Primary completion
Aug 1, 2009
Completion
Aug 5, 2009
Results posted
Mar 22, 2018
Last update
Mar 22, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion